Amgen Stock News

THOUSAND OAKS, Calif. , Feb. 22, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the issuance of its inaugural $750 million green bond, with a 3.000% semi-annual coupon and maturing in 2029, to advance the environmental goals that are part of Amgen ''s environmental, social and governance

Healthcare is the smart play in this bear market. Here''s why these three Fool.com contributors like Doximity, Amgen, and Novocure.

Healthcare is the smart play in this bear market. Here's why these three Fool.com contributors like Doximity, Amgen, and Novocure.

A business's management is an important, if not the most important, part of an investment decision.

The trading price of Amgen Inc. (NASDAQ:AMGN) floating lower at last check on Wednesday, February 16, closing at $222.27, -0.74% lower than its previous close. >> 5 Best Growth Stocks for 2022 << >> 5 Best Growth Stocks for 2022 << Traders who pay close attention to intraday price movement should know that it has … Making Sense Of Amgen Inc.’s (NASDAQ:AMGN) Volatility Read More »

Japan''s regulatory agency recently authorized Lumakras as a treatment for a type of lung cancer.

Japan's regulatory agency recently authorized Lumakras as a treatment for a type of lung cancer.

Amgen Inc (NASDAQ: AMGN ) announced the presentation of efficacy and safety data from the CodeBreaK 100 Phase 1/2 trial in KRAS G12C-mutated advanced pancreatic cancer patients who received Lumakras (sotorasib). The data will be presented at the American Society of Clinical Oncology (ASCO) Plenary Series. Data show encouraging and clinically meaningful anticancer activity and … Full story available on Benzinga.com

Amgen Inc (NASDAQ: AMGN ) announced the presentation of efficacy and safety data from the CodeBreaK 100 Phase 1/2 trial in KRAS G12C-mutated advanced pancreatic cancer patients who received Lumakras (sotorasib). The data will be presented at the American Society of Clinical Oncology (ASCO) Plenary Series. Data show encouraging and clinically meaningful anticancer activity and … Full story available on Benzinga.com

Amgen Inc (NASDAQ: AMGN) announced the presentation of efficacy and safety data from the CodeBreaK 100 Phase 1/2 trial in KRAS G12C-mutated advanced pancreatic cancer patients who received Lumakr

If any investor has stood the test of time, it is Warren Buffett, and with good reason.

These seven top defensive growth stocks are among the best options for investors looking for growth, but with a risk-off perspective. The post 7 Defensive Growth Stocks to Buy for February appeared fi

Someone with a lot of money to spend has taken a bearish stance on Amgen (NASDAQ: AMGN ). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don''t know. But when something this big happens with AMGN, it often means somebody knows something is about to happen. So how do we know what this whale just did? Today, Benzinga ''s options scanner spotted 12 uncommon options trades for Amgen. This isn''t normal. The overall sentiment of these big-money traders is split between 25% bullish and 75%, bearish. Out of all of the special options we uncovered, 4 are puts, for a total amount of $2,457,250, and 8 are calls, for a total amount of $345,737. What''s The Price Target? Taking into account the Volume and Open … Full story available on Benzinga.com

The U.S. inflation jumped to 7.5% in January but that doesn't necessarily have to mean “losses” for equity investors. According to Grace Capital's Catherine Faddis, the following three stocks have